Le Lézard
Classified in: Health
Subject: ACC

Bulletin from annual general meeting in Medicover AB (publ)


STOCKHOLM, April 27, 2022 /PRNewswire/ -- The below resolutions were passed at Medicover's annual general meeting (the "AGM") held today on 27 April 2022. In accordance with the Act (2022:121) on temporary exceptions to facilitate the execution of general meetings in companies and other associations, the AGM was carried out through postal voting without any physical attendance.

Election of the board of directors and auditor

The AGM resolved, in accordance with the proposal from the nomination committee, that the number of board members appointed by the shareholders' meeting shall be ten. Fredrik Stenmo, Peder af Jochnick, Robert af Jochnick, Arno Bohn, Sonali Chandmal, Michael Flemming, Margareta Nordenvall and Fredrik Rågmark were re-elected, whereas Anne Berner and Azita Shariati were elected, as board members. Fredrik Stenmo was re-elected as the chairman of the board. The AGM resolved that the number of auditors shall be one without deputies and to re-elect BDO Sweden AB as the company's auditor, with Jörgen Lövgren as auditor in charge, which is in accordance with the audit committee's recommendation.

Fees to board members and auditor

The AGM resolved that the fees to the board members shall be paid out in a total amount of EUR 581,350, divided so that the chairman of the board of directors shall receive EUR 74,000 and the other board members who are not employed by the group shall receive EUR 53,000 each, the chairman of the audit committee shall receive EUR 23,000 and each other member of the audit committee who is not employed by the group shall receive EUR 11,250 each, the chairman of the remuneration committee shall receive EUR 8,200 and each other member of the remuneration committee who is not employed by the group shall receive EUR 8,200 each, as well as EUR 5,100 for the chairman of the sustainability committee and EUR 5,100 for each other member of the sustainability committee who is not employed by the group. It was resolved that the auditor's fees shall be paid as per approved account.

Adoption of the annual accounts, allocation of the results and discharge from liability

The AGM resolved to adopt the annual accounts for the company and the group for 2021. In accordance with the proposal from the board of directors, the AGM determined that dividend of EUR 0.12 per share shall be paid for 2021 and record date for dividend is Friday 29 April 2022. Euroclear Sweden AB is expected to disburse dividend on Friday 6 May 2022. The last day for trading in the company's share including right to dividend is Wednesday 27 April 2022. Furthermore, the AGM resolved to discharge the board members and the CEO from liability.

Remuneration report

The AGM approved the remuneration report prepared by the board of directors.

Instructions to the nomination committee

The AGM adopted the nomination committee's proposed instructions to the nomination committee.

Guidelines for remuneration to senior executives

The AGM adopted the board of directors' proposed guidelines for remuneration to senior executives.

Long term performance-based share program

The AGM resolved, in accordance with the proposal from the board of directors, to adopt a long term performance-based share program for group management and other key individuals within the Medicover group, including a maximum of 93 participants. The participants in the program are required to invest in Medicover by investing in Class B shares in the company. The participants will, provided that certain conditions are met, be granted Class B shares free of charge. Further, the AGM resolved, in accordance with the proposal from the board of directors, to adopt certain hedging arrangements in order to secure the delivery of shares to the participants at the end of the program. The hedging arrangements include an authorisation for the board of directors to issue a maximum of 1,344,440 Class C shares, of which not more than 58,440 Class C shares may be issued to secure social charges, an authorisation for the board of directors to repurchase all issued Class C shares and a resolution to transfer the repurchased shares, following reclassification into Class B shares, to the participants in the program as well as in the market in order to cover the cash flow effects arising as a result of payments of social charges.

Authorisation for the board of directors to resolve to issue new shares

The AGM authorised, in accordance with the proposal from the board of directors, the board of directors to, at one or several occasions and for the period until the next annual general meeting, resolve to issue new Class B shares. The purpose is to increase the financial flexibility of the company and the acting scope of the board of directors. The authorisation allows the board of directors to resolve to increase the company's share capital by issue of new shares at one or several occasions and for the time period until the end of the next annual general meeting, with or without deviation from the shareholders' preferential rights and with or without provisions for contribution in kind, set-off or other conditions, to the extent that it corresponds to a dilution of not more than ten per cent of the number of shares outstanding at the time of the shareholders' meeting's resolution on the proposed authorisation.

Authorisation for the board of directors to resolve to repurchase own shares

The AGM authorised, in accordance with the proposal from the board of directors, the board of directors to resolve upon repurchases of own shares of class B, on one or several occasions prior to the annual general meeting 2023. The purpose of the authorisation is to promote efficient capital usage in the company and to provide flexibility as regards the company's possibilities to distribute capital to its shareholders. Repurchase shall maximum comprise so many shares of class B that the company's holding does not at any time exceed ten per cent of the total number of shares in the company. Repurchase may only take place on Nasdaq Stockholm and only at a price within the price range applicable at any given time, i.e. the range between the highest purchase price and the lowest selling price.

The underlying proposals to the above resolutions are published, and at the latest on 11 May 2022 also the minutes from the AGM will be published, at www.medicover.com.

For further information, please contact:

Hanna Bjellquist, Head of Investor Relations

+46 703 033 272
hanna.bjellquist@medicover.com

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2021, Medicover had revenue of EUR 1,377 million and more than 38,000 employees. For more information, go to www.medicover.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medicover/r/bulletin-from-annual-general-meeting-in-medicover-ab--publ-,c3554596

The following files are available for download:

https://mb.cision.com/Main/15662/3554596/1570108.pdf

Bulletin from AGM 2022


These press releases may also interest you

at 14:40
Over the past decade, countless dedicated athletes, fitness lovers, and everyone in between have made Thermovextm by EVOchem Nutrition® a necessary and favorite staple in their everyday routine. This metabolic/thermogenic powerhouse has even garnered...

at 14:35
Following the FDA approval of ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions, today bluebird bio released...

at 14:34
Xenocor, a Utah-based medical device company, today announced newly issued U.S. patent protection for the Saberscope system from the United States Patent and Trademark Office (USPTO). The Saberscope system is the world's first true HD, fog free,...

at 14:30
According to Coherent Market Insights, the global remote patient monitoring devices market is estimated to be valued at US$ 1,192.5 million in 2022 and is expected to exhibit a CAGR of 7.4 % during the forecast period (2022-2030). Key Trends and...

at 14:29
The Partnership for Quality Home Healthcare (the Partnership) today announced the results of a newly conducted national public opinion poll on the Medicare Home Health Program. The poll found widespread and deep support for Medicare home health care...

at 14:10
MicroGEM, a U.S.-based molecular biology company, today announced that Medline, a manufacturer and distributor of medical supplies to healthcare providers across the continuum of care, is now offering the MicroGEM Sal6830 Point of Care PCR System and...



News published on 27 april 2022 at 08:09 and distributed by: